Calendar

Cloudflare’s reported Q2 2026 revenue growth and a $736.8M Q3 revenue consensus provide a credible business backdrop, but the stock fell sharply into the event: it lost roughly 15.5% from Oct. 26 to Oct. 30, including a high-volume down day. Required positive tape and estimate-upside signals are not supported.

ABNB has a small positive whisper-versus-consensus gap and recent company guidance describes strong revenue growth, but the guidance midpoint is slightly below the checked revenue consensus. The stock fell about 4.4% over five sessions, had no close above the 0.75 close-location threshold in the latest three sessions, and no confirmed 1.5x volume session; it does not qualify despite a supportive XLY tape.

EOG has upward EPS estimate revisions, a credible Q3 consensus, and a strong Oct. 30 close, but available checks did not establish positive revenue revisions or a recent >1.5x-volume accumulation day. The company has scheduled its Q3 results for Nov. 5 after close; its IR page separately lists a Nov. 6 results call.

Lumentum's September-quarter EPS estimate rose from $4.21 to $4.22 over the last month, and its prior company guidance midpoint for $1.25B revenue is in line with reported consensus; management cited accelerating AI-driven optical demand and the stock advanced sharply over the preceding five sessions. However, the late-week reversal and lack of a verified normal-volume comparator temper the setup, while valuation and execution risks remain material.

Simon has positive, though non-uniform, estimate momentum: checked consensus showed EPS up 1.74% and revenue up 3.69% over three months, and its latest reported quarter showed 96.0% occupancy, higher retailer sales, and raised full-year FFO guidance. The stock gained about 2.4% over five sessions and closed near the top of its Oct 30 range, but a normal-volume comparison was unavailable and its recent earnings history is uneven.

DVN has positive near-term estimate revisions, rising revenue expectations, four recent EPS beats per Zacks, and an official Nov. 5 reporting date; the stock also strengthened into the event. However, earnings-whisper EPS is below some consensus figures and the shares lagged the energy sector over the past month, while commodity exposure and transaction execution leave meaningful uncertainty.

Earnings Whispers reports a $1.48 whisper against $1.39 consensus, while the prior quarter had strong reported growth; however, no reliable pre-event revenue-revision, verified close-location, or volume-accumulation evidence was found for this screen, and the supplied latest close does not establish recent strength. The positive whisper alone is insufficient for qualification.

ED's reported date and consensus figures were available, and the recent close rose with XLU supportive; Con Edison had reaffirmed its 2026 adjusted EPS guidance. But no positive EPS revision, ESP, whisper, or revenue-upside signal was verified, and none of the last three checked sessions closed in the upper quarter of its range.

A pre-event Zacks article says the estimate-revision combination points toward a likely EPS beat, and recent annualized recovery expectations offer a possible cyclical catalyst. However, exact revision and current-quarter revenue consensus/upside evidence was not verifiable in the checked results, while Oct. 30 brought a high-volume 4.66% selloff and a weak close; it fails the required tape confirmation.

Live Nation has strong operating indicators ahead of the report: the latest available filing said 2026 event ticket sales were pacing 11% higher and deferred revenue reached a second-quarter record, while the stock recovered into Oct. 30 on a large-volume up day. But current-quarter revenue consensus estimates varied across checked providers and no positive EPS revision/ESP/whisper was verified; score remains below the required threshold.

The supplied Nov. 5 date conflicts with checked earnings sources: Earnings Whispers and MarketBeat indicate Nov. 4, while another estimate page shows Nov. 5 and cautions the date may move. Consensus estimates exist, but no positive revisions or required tape confirmation were established; reject on unconfirmed event date and incomplete signals.

MRNA has a modestly favorable EPS revision snapshot and a recent high-volume rebound, but the checked calendar sources describe Nov. 6 as estimated rather than company-confirmed, and no positive revenue revision or upside indicator was verified. The Oct. 22 melanoma-trial data leak coincided with a 17.57% drop and unusually high volume, leaving a volatile, event-driven tape.

Record Q2 fundraising and 20% fee-related-earnings growth, alongside a rising recent share price and several analyst target cuts, create a constructive but mixed backdrop. The checked sources support EPS and revenue consensus, but do not establish positive estimate revisions or an upside surprise signal; recent volume also falls short of a verified accumulation trigger.

Humana's primary IR estimate table showed near-flat Q3 EPS revisions and a credible consensus source provides EPS and revenue estimates, but the stock weakened into the event and underperformed the rising XLV. Medical-cost and Medicare policy uncertainty remain material, while recent tape did not confirm accumulation.

Vistra has a company-confirmed Nov. 6 report date and a strongly positive 30-day Q3 EPS revision, alongside long-term power-demand catalysts. However, shares declined about 5.4% from Oct. 26 through Oct. 30, recent closes were weak in their daily ranges, and the latest quarter missed consensus materially. Positive revisions alone do not offset the poor pre-event tape and limited recent execution evidence.

The earnings follow-up materially improves evidence over the April monitoring baseline, consistent with the deterministic score’s positive directional prior and high thesis-change score. Market validation remains weak: after the October 7 after-close release, LEVI fell from $19.51 at that close to $18.70 on October 9, about 4.2%, while several analysts cut targets. The October 7 trading decline preceded the release and should not be attributed to it. Price weakness and target cuts temper the EPS beat and raised guidance; the apparent refund-driven margin benefit makes Q4 DTC and underlying profitability the decisive checks. No reliable social, options, short-interest or employee measures were supplied. [Price history](https://stockanalysis.com/stocks/levi/history/) [Analyst revisions](https://www.tipranks.com/stocks/levi/forecast)

This T+1 earnings update is mixed-to-negative: AP reported that shares rose about 2% on October 8 following the quarterly beat, even as PepsiCo lowered its annual profit outlook. One reported post-print target cut is available, but broader analyst estimate revisions and whether the initial price reaction holds are not yet established. Social, options-skew, short-interest and employee-score fields are unavailable; their zero placeholders are not measurements. [AP report](https://apnews.com/article/56f06d9d9e470785e094323869e6d695) [Goldman target report](https://www.tipranks.com/news/the-fly/pepsico-price-target-lowered-to-165-from-180-at-goldman-sachs-thefly-news)

The confirmed earnings release was September 29; the packet's October 8 scheduled earnings date does not identify a new company print. Shares closed at $32.90 on September 28, $32.36 on release day, $29.78 on September 30 and $32.28 on October 8. This shows an initial decline and subsequent recovery, but does not establish what caused either move. [Historical closes](https://stockanalysis.com/stocks/intg/history/) Consensus surprise figures, company guidance revisions and reliable post-print analyst target changes were unavailable. The positive deterministic prior reflects stronger operating evidence, but thin coverage and uncertain recurring cash generation warrant a monitoring stance. No social, options, short-interest or employee-sentiment measurements were supplied.

The company reported an adjusted EPS beat and reiterated guidance, yet ANGO fell 20.9% on October 8 from the prior close. That reaction materially tempers the prior positive thesis; it should not be explained solely by guidance or CEO succession without firmer evidence. Trusted post-print analyst revisions were unavailable, and published revenue-consensus figures disagree. The sentiment numeric zeros denote unavailable readings, not neutral measurements. [SEC earnings exhibit](https://www.sec.gov/Archives/edgar/data/1275187/000114036126039020/ef20083493_ex99-1.htm); [price history](https://stockanalysis.com/stocks/ango/history/).

This is a pre-earnings monitoring view, not a T+1 results assessment. The October 8 price anchor precedes the company-announced October 19 release, so post-release price reaction, earnings surprise, guidance revisions, and analyst target changes are unavailable. Sentiment numeric fields are unavailable-data placeholders, not measured readings. The deterministic prior is positive, but its evidence-quality score is only 0.16 and uncertainty is 0.862; the erroneous event date and loose peers warrant lower conviction. [#PR-2026-10-05] [#SEC-6K-2026-10-05]

WS closed at $35.56 on October 7, down 6.89% from its October 6 close of $38.19, then fell to the packet's $34.62 October 8 anchor. The approximately 9.3% two-session decline had not reversed by that close. News coverage characterized adjusted EPS as a miss, but published consensus figures conflict. The company-confirmed combined results and conditional integration plan support a monitoring view; no dependable post-earnings analyst target or estimate revision was verified by this T+3 follow-up. https://stockanalysis.com/stocks/ws/history/ https://finance.yahoo.com/markets/stocks/articles/worthington-steel-falls-short-q1-210347210.html